Treatment-related toxicity and supportive care in metastatic colorectal cancer

Journal of Supportive Oncology

Volumn 8, Issue 1, 2010, Pages 15-20

  Zafar, S Yousuf ^a   Marcello, Jennifer E ^a   Wheeler, Jane L ^a   Rowe, Krista L ^a   Morse, Michael A ^a   Herndon II, James E ^a   Abernethy, Amy P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; ANTIINFLAMMATORY AGENT; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CETUXIMAB; ERYTHROPOIETIN; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; OPIATE; OXALIPLATIN; PANITUMUMAB; STEROID;

ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CARDIOTOXICITY; COLORECTAL CANCER; COLORECTAL METASTASIS; DEMOGRAPHY; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ERYTHROPOIESIS; FEMALE; GASTROINTESTINAL TOXICITY; GRANULOCYTE; HEMATOLOGIC DISEASE; HOSPITALIZATION; HUMAN; INFECTION; INFORMATION PROCESSING; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; PAIN; POPULATION RESEARCH; RETROSPECTIVE STUDY; SEXUAL DYSFUNCTION; SKIN TOXICITY; SOCIAL SUPPORT; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PALLIATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77649197894     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.[10944126]
2. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-1047.[10744089]
3. Maindrault-Goebel F, Louvet C, André T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 1999;35:1338-1342. [10658524]
4. André T, Louvet C, Maindrault-Goebel F, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999;35:1343-1347. [10658525]
5. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.[15269313]
6. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.[15175435]
7. Hecht JR, Patnaik A, Berlin J, et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 2007;110:980-988. [17671985]
8. Goldberg RM, Rothenberg ML, Van Cutsem E, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 2007;12:38-50.[17227899]
9. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.[11006366]
10. Green E, Sargent DJ, Goldberg RM, Grothey A. Detailed analysis of oxaliplatin-associated neurotoxicity in Intergroup trial N9741. 2005 Gastrointestinal Cancers Symposium. Hollywood, FL. Abstract 182.
11. Grothey A, Deschler B, Kroening H, et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002;21:512.
12. Van Cutsem E. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist 2006;11:1010-1017.[17030643]
13. Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 2006;33(5 suppl 10):S26-S34.[17145522]
14. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007;25:4779-4786.[17947725]
15. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008;26:3523-3529. [18640933]
16. Elting LS, Cooksley C, Bekele BN, et al. Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer 2006;106:2452-2458.[16639738]
17. Cottin V, Arpin D, Lasset C, et al. Small-cell lung cancer: patients included in clinical trials are not representative of the patient population as a whole. Ann Oncol 1999;10:809-815.[10470428]
18. André T, Bensmaine MA, Louvet C, et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999;17:3560-3568.[10550155]
19. Goldberg RM, Sargent DJ, Morton RF, et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 2006;24:3347-3353.[16849748]
20. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 2006;24:394-400.[16421419]
21. Maindrault-Goebel F, Lledo G, Chibaudel B, et al. Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): a GERCOR study. J Clin Oncol 2007;25(18S):4013.
22. Sun VC, Borneman T, Ferrell B, Piper B, Koczywas M, Choi K. Overcoming barriers to cancer pain management: an institutional change model. J Pain Symptom Manage 2007;34:359-369.[17616336]
23. Basch E, Iasonos A, Barz A, et al. Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol 2007;25:5374-5380.[18048818]
24. Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 2008;26:1355-1363.[18227528]
25. Trotti A, Colevas AD, Setser A, Basch E. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol 2007;25:5121-5127.[17991931]
26. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, V.1.2009. www.nccn.org/professionals/physician-gls/f-guidelines. asp. Accessed August 8,2009.
27. Multinational Association of Supportive Care in Cancer. www.mascc.org. Accessed August 8, 2009.
28. Jensen K, Bonde Jensen A, Grau C. The relationship between observer-based toxicity scoring and patient assessed symptom severity after treatment for head and neck cancer: a correlative cross sectional study of the DAHANCA toxicity scoring system and the EORTC quality of life questionnaires. Radiother Oncol 2006;78:298-305.[16524633]
29. Petersen M, Pedersen L, Groenvold M. Does the agreement of patient and physician assessments of health related quality of life in palliative care depend on patient characteristics? Palliat Med 2007;21:289-294.[17656405]